⌕
Syndax Pharmaceuticals · SNDX · Nasdaq
Tenet 49 · Mixed
Compare
$9.13−3.39%At closeTenet 49 · Mixed
$9.13−0.32 (−3.39%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Syndax Pharmaceuticals (SNDX) Stock

Syndax Pharmaceuticals (SNDX) closed at $9.13 on Nov 16, 2026; its Tenet Score is 49 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$9.13
Nov 16, 2026
Market cap
$843.9M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
9.11 – 25.59
low → high · as of close, Nov 13, 2026
Tenet Score
49/100
Mixed · 313 Healthcare peers

Industry: Drugs

Syndax Pharmaceuticals Inc scores 49/100. Mixed. Strongest on financial health, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 49 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
49/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
24
Health
68
Growth
55

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityFHealthCGrowthCMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
2.9×
price to fiscal 2025 sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−158.4%
fiscal 2025, before interest and tax
Net margin
−72.4%
of revenue kept
Current ratio
4.69
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mix…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 55 US ETFs · top wrappers by weightSee all ETFs holding SNDX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Syndax Pharmaceuticals in?

Syndax Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Syndax Pharmaceuticals' Tenet Score?

Syndax Pharmaceuticals' Tenet Score is 49 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.